AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 34706172
Drug: Risankizumab (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risankizumab (90 mg, subcutaneously once every 4 weeks)
Trial: 33948911
Drug: Atogepant (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atogepant (60 mg) co-administered with Acetaminophen (1000 mg)
Trial: 33948911
Drug: Atogepant (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atogepant (60 mg) co-administered with Naproxen (500 mg)
Trial: 33948911
Drug: Atogepant co-administered
RxNorm normalized name: Atogepant
DrugBank: Atogepant (DB16098)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atogepant co-administered with Acetaminophen
Trial: 33948911
Drug: Atogepant co-administered
RxNorm normalized name: Atogepant
DrugBank: Atogepant (DB16098)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atogepant co-administered with Naproxen
Trial: 34384001
Drug: Telmisartan 80
RxNorm normalized name: telmisartan 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan 80 mg + Rosuvastatin (10 or 20 mg) SPC
Trial: 34384001
Drug: Telmisartan 80
RxNorm normalized name: telmisartan 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan 80 mg monotherapy
Trial: 32091599
Drug: Low-nitrate vegetables
RxNorm normalized name: Hydrogenated Vegetable Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-nitrate vegetables + placebo pills
Trial: 32091599
Drug: Low-nitrate vegetables
RxNorm normalized name: Hydrogenated Vegetable Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-nitrate vegetables + nitrate pills (300 mg nitrate)
Trial: 32091599
Drug: Leafy green
RxNorm normalized name: Green tea leaf
DrugBank: Green tea leaf (DB14307)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leafy green vegetables containing 300 mg nitrate + placebo pills
Trial: 33035741
Drug: Nonstarters (compared
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonstarters (compared to treatment starters)
Trial: 34229085
Drug: Lavender oil
RxNorm normalized name: Lavender oil
DrugBank: Lavender oil (DB14566)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lavender oil inhalation for 15 min before dressing (Lavender‐15 Group)
Trial: 34229085
Drug: Lavender oil
RxNorm normalized name: Lavender oil
DrugBank: Lavender oil (DB14566)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lavender oil inhalation for 60 min before dressing (Lavender‐60 Group)
Trial: 34229085
Drug: Control Group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control Group inhaled jojoba (placebo) oil for 15 min before dressing
Trial: 33932193
Drug: Endophytic fungi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endophytic fungi selected for L‐asparaginase (L‐ASNase) production test (20 isolates).
Trial: 33932193
Drug: Phyllosticta catimbauensis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phyllosticta catimbauensis URM 7672 for partial optimisation of L‐ASNase production.
Trial: 33206039
Drug: Precision clinical
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Precision clinical trial framework including treatment‐targeted enrichment, adaptive treatments, and precise measurement.
Trial: 34189995
Drug: PRC-063 (Extended-Release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRC-063 (Extended-Release Methylphenidate)
Trial: 32570811
Drug: Leucine-enriched protein
RxNorm normalized name: Leucine
DrugBank: Leucine (DB00149)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Leucine-enriched protein supplement (leucine 3 g, protein mixture 17 g, vitamin D 800 IU, calcium 300 mg, fat 1.1 g, carbohydrate 2.5 g)
Trial: 32570811
Drug: Isocaloric carbohydrate
RxNorm normalized name: pyrrolidone carboxylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isocaloric carbohydrate supplement
Trial: 36173236
Drug: Bionic Pancreas
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bionic Pancreas (BP) with insulin aspart or insulin lispro (N=107)
Trial: 33796452
Drug: Trastuzumab therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trastuzumab therapy
Trial: 34343296
Drug: Metformin followed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin followed by glipizide and then insulin glargine on failure to achieve HbA1c < 6.5%
Trial: 34343296
Drug: Initial triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial triple therapy with metformin/pioglitazone/exenatide
Trial: 33778929
Drug: Etrolizumab 105
RxNorm normalized name: Etrolizumab
DrugBank: Etrolizumab (DB12189)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etrolizumab 105 mg by Autoinjector (AI)
Trial: 33778929
Drug: Etrolizumab 105
RxNorm normalized name: Etrolizumab
DrugBank: Etrolizumab (DB12189)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etrolizumab 105 mg by Prefilled Syringe with Needle Safety Device (PFS‐NSD)
Trial: 34974502
Drug: 6 g
RxNorm normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 g of l-Citrulline (CIT)
Trial: 33582575
Drug: Opioid receptor
RxNorm normalized name: Opioid receptor agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opioid receptor antagonist naltrexone (NAL)
Trial: 32619868
Drug: Sublingual buprenorphine-naloxone
RxNorm normalized name: buprenorphine / naloxone Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual buprenorphine-naloxone (BUP-NX)
Trial: 33693835
Drug: Dietary intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dietary intervention (280 g whole blueberries and 12 g soluble fiber per day)
Trial: 33494380
Drug: Transconjunctival injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transconjunctival injection of BTX‐A (3 units); n = 15, 25 eyes
Trial: 33494380
Drug: Transcutaneous injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcutaneous injection of BTX‐A (3 units); n = 16, 28 eyes
Trial: 32955964
Drug: Herbarium mixture
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herbarium mixture (G. ulmifolia/T. stans) 400 mg before each meal for 90 days
Trial: 33066862
Drug: Nardostachys jatamansi
RxNorm normalized name: Nardostachys chinensis root extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nardostachys jatamansi (3 g total, 1 capsule 3 times a day for 4 weeks)
Trial: 36299870
Drug: Combined topical
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined topical airway anesthesia induction strategy (aerosol inhalation airway anesthesia, subglottic airway anesthesia, and low-dose intravenous anesthetics)
Trial: 36299870
Drug: Conventional induction
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional induction group (high-dose intravenous anesthetics)
Trial: 36329428
Drug: PRP +
RxNorm normalized name: Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRP + Artz (2.5 ml, 10 mg/ml HA followed by 3 ml PRP)
Trial: 36329428
Drug: PRP +
RxNorm normalized name: Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRP + HYAJOINT Plus (3 ml, 20 mg/ml cross‐linked HA followed by 3 ml PRP)
Trial: 34629067
Drug: 50% calorie-restricted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50% calorie-restricted and ketogenic diet combined with aerobic exercise during intravenous chemotherapy
Trial: 32769919
Drug: LED photobiomodulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LED photobiomodulation therapy 3 times a week for 2 weeks
Trial: 32769919
Drug: Sham therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham therapy 3 times a week for 2 weeks
Trial: 35283313
Drug: ChAdOx1 followed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ChAdOx1 followed by an mRNA vaccine
Trial: 35283313
Drug: Spike‐ACE2‐receptor‐blocking antibodies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spike‐ACE2‐receptor‐blocking antibodies
Trial: 32756845
Drug: MS/2 medium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MS/2 medium supplemented with 100 mg L‐1 of cysteine, 0.5 mg L‐1 of gibberellic acid (AG3) and 30 g L‐1 of sucrose
Trial: 34812713
Drug: Pharmacological treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacological treatment (fluoxetine)
Trial: 34812713
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (CBT) and/or pharmacological treatment
Trial: 33139781
Drug: Presence of
RxNorm normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Presence of anti-Toxoplasma gondii antibodies in MS patients
Trial: 33139781
Drug: Presence of
RxNorm normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Presence of anti-Toxoplasma gondii antibodies in controls
Trial: 35875890
Drug: Vutrisiran 25
RxNorm normalized name: VUTRISIRAN 25MG/0.5ML SOLN INJ SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vutrisiran 25 mg every 3 months (Q3M)
Trial: 32881639
Drug: Post-discharge phone
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-discharge phone calls from a navigator to review the recommended treatment plan and address barriers to engagement on days 3, 7, 14, and 21
Trial: 32282720
Drug: Electroacupuncture (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroacupuncture (EA) and electronic moxibustion (EM) + alpha blocker
Trial: 33317802
Drug: Physostigmine 0.5
RxNorm normalized name: physostigmine 0.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physostigmine 0.5 mg h−1 i.v. for 24 h
Trial: 35341724
Drug: Sham therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham therapy (control group)
Trial: 32200817
Drug: 20 Gy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 Gy of external beam therapy
Trial: 35546527
Drug: Everolimus regimen
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Everolimus regimen (low dose CNI, everolimus, and prednisolone)
Trial: 35119460
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of visual campaign and narrative vignette from the perspective of a patient with OUD
Trial: 35119460
Drug: Combined visual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined visual campaign and patient vignette about the value of medication treatment for OUD
Trial: 34520219
Drug: VRD treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VRD treatment
Trial: 32799981
Drug: Prescriptions for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescriptions for children under five years
Trial: 34907041
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment of double plasma molecular adsorption system (DPMAS) and low volume plasma exchange (PE)
Trial: 34907041
Drug: Comprehensive internal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive internal medical treatment (as part of the trial group)
Trial: 34907041
Drug: Comprehensive internal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive internal medical treatment (control group)
Trial: 36701139
Drug: Calcium (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium (1200 mg)
Trial: 34991130
Drug: Zishen Yutai
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zishen Yutai Pill
Trial: 32340780
Drug: SGLT2 inhibitors
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SGLT2 inhibitors (general reference)
Trial: 34228127
Drug: Counseling plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Counseling plus nicotine replacement therapy (NRT)
Trial: 32857992
Drug: 1 +
RxNorm normalized name: Prenatal Vitamins Oral Tablet [PRENAZYME 1 + 1]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 + 1 dosing schedule of PCV13 (6w + 1 and 14w + 1 groups)
Trial: 32857992
Drug: 1 +
RxNorm normalized name: Prenatal Vitamins Oral Tablet [PRENAZYME 1 + 1]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 + 1 dosing schedule of PCV10 (6w + 1 and 14w + 1 groups)
Trial: 32857992
Drug: 2 +
RxNorm normalized name: dHER2 + AS15 ASCI
DrugBank: SB719125 (DB16753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 + 1 dosing schedule of PCV13
Trial: 32857992
Drug: 2 +
RxNorm normalized name: dHER2 + AS15 ASCI
DrugBank: SB719125 (DB16753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 + 1 dosing schedule of PCV10
Trial: 35260448
Drug: Intensive Nutrition
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive Nutrition Therapy
Trial: 32513192
Drug: Habit-forming interventions
RxNorm normalized name: docusate
DrugBank: Docusate (DB11089)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Habit-forming interventions (e.g., having a relative ask about pill-taking, re-packaging medications, leaving medications in view, using alarms, carrying water, linking pill-taking to radio/prayer schedules)
Trial: 33891348
Drug: Fremanezumab monthly
RxNorm normalized name: Fremanezumab
DrugBank: Fremanezumab (DB14041)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fremanezumab monthly (675/225/225 mg)
Trial: 33849494
Drug: 30 g
RxNorm normalized name: Lancet Unilet 30 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 g of oat bran daily for 4 weeks at lunch and dinner
Trial: 32296094
Drug: Compeed Patches
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compeed Patches
Trial: 32296094
Drug: Zovirax Cream
RxNorm normalized name: acyclovir Topical Cream [Zovirax]
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zovirax Cream (5% acyclovir)
Trial: 33037518
Drug: Getong Tongluo
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Getong Tongluo Capsule (GTC) 250 mg plus EGB-matching placebo 40 mg (GTC group)
Trial: 33037518
Drug: EGB 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EGB 40 mg plus GTC-matching placebo 250 mg (EGB group)
Trial: 33037518
Drug: GTC-matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GTC-matching placebo 250 mg plus EGB-matching placebo 40 mg (Placebo group)
Trial: 33037518
Drug: Getong Tongluo
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Getong Tongluo Capsule (GTC) 250 mg
Trial: 33037518
Drug: EGB 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EGB 40 mg
Trial: 35629000
Drug: Anti-disgust cognitive
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-disgust cognitive behavioral therapy (AD-CBT)
Trial: 32716603
Drug: Oral irrigator
RxNorm normalized name: Irrigation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral irrigator with 0.06% CHX solution
Trial: 32716603
Drug: Oral irrigator
RxNorm normalized name: Irrigation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral irrigator with water
Trial: 32716603
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (oral hygiene instruction and mechanical debridement)
Trial: 32668456
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg albendazole
Trial: 32016292
Drug: Filgotinib, 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Filgotinib, 200 mg
Trial: 32016292
Drug: Filgotinib, 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Filgotinib, 100 mg
Trial: 34236303
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg phentermine
Trial: 34236303
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg phentermine
Trial: 34236303
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg and 30 mg phentermine
Trial: 35924312
Drug: Internet-delivered cognitive
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-delivered cognitive behaviour therapy (iCBT)
Trial: 33478567
Drug: Triple low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Triple low-dose antihypertensive drug combination
Trial: 33478567
Drug: Dual drug
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual drug combination
Trial: 33478567
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care (monotherapy followed by dual treatment)
Trial: 33478567
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care with optional dose titration after 4 and 8 weeks
Trial: 34182929
Drug: Multimodal analgesia
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal analgesia (pre-operative acetaminophen and gabapentin, intra-operative flurbiprofen and ropivacaine, post-operative acetaminophen and celecoxib)
Trial: 35420672
Drug: Bortezomib added
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bortezomib added to decitabine therapy
Trial: 35420672
Drug: Dependence in
RxNorm normalized name: Vitamin K-dependent protein S
DrugBank: Protein S human (DB13149)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dependence in instrumental activities of daily living
Trial: 39118415
Drug: Chelation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chelation therapy
Trial: 32679201
Drug: Nasal high-flow
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal high-flow treatment
Trial: 35650612
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose of Gyejibokryeong-hwan (GBH)
Trial: 35650612
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose of Gyejibokryeong-hwan (GBH)
Trial: 32217561
Drug: azithromycin 500
RxNorm normalized name: azithromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: azithromycin 500 mg one time per day for 3 days
Trial: 32217561
Drug: amoxicillin 1
RxNorm normalized name: amoxicillin 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: amoxicillin 1 g three times per day for 5 days
Trial: 32217561
Drug: standard-of-care (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard-of-care (no immediate antibiotic)
Trial: 32217561
Drug: azithromycin and
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: azithromycin and amoxicillin (combined)
Trial: 34865452
Drug: rb‐bFGF gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rb‐bFGF gel
Trial: 34865452
Drug: gel matrix
RxNorm normalized name: Sil_k Pad Gel Matrix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gel matrix
Trial: 34717154
Drug: IRX-2 regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IRX-2 regimen (low dose 300 mg/m2 cyclophosphamide on day 1, followed by 10 days of regional perilymphatic IRX-2 cytokine injections and daily oral indomethacin, zinc, and omeprazole)
Trial: 35040196
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment (INT)
Trial: 35040196
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (CONV)
Trial: 35927828
Drug: Honey-flavoured syrup
RxNorm normalized name: Honey
DrugBank: Honey (DB14242)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Honey-flavoured syrup placebo
Trial: 33653284
Drug: 7-day proton-pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-day proton-pump inhibitor-clarithromycin containing standard triple therapy (STT)
Trial: 36434615
Drug: Oral nutritional
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral nutritional supplements (ONS) with a high-protein-high calorie mixture containing immunonutrients (Impact®) plus nutritional counseling
Trial: 32636985
Drug: Intermittent pneumatic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent pneumatic compression plus standard compression therapy
Trial: 32636985
Drug: Control (compression
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (compression therapy alone)
Trial: 34347947
Drug: Mepolizumab 100
RxNorm normalized name: mepolizumab 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mepolizumab 100 mg every 4 weeks
Trial: 34347947
Drug: Mepolizumab 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mepolizumab 300 mg every 4 weeks
Trial: 34347947
Drug: Mepolizumab (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mepolizumab (both doses)
Trial: 32877266
Drug: Patching therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patching therapy (14–42 hours per week)
Trial: 35963274
Drug: NVX-CoV2373 (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NVX-CoV2373 (5 μg SARS-CoV-2 rS with 50 μg Matrix-M adjuvant)